Prisyna Gets $6M For Oral Health Products

Claremont-based Prisyna, a unit of Synedgen, said this morning that it has raised $6M in a growth equity investment, to help it advance its products. The funding came from Andrew Miller. Prisyna is developing a treatment called Moistagen, which it says relieves the symptoms of dry mouth, as well as treats oral mucositis due to chemotherapy or radiation treatments. The company currently offers two oral rinse products under the Synedent name, Synedent Oral Care and Synedent Plus Oral Care with flouride. The company says it has two evaluations under way of its product, at a private practice in Los Angeles and Tufts University School of Dental Medicine in Boston.